Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avandia rosiglitazone regulatory update

The U.K.'s MHRA revised the prescribing information for Avandia rosiglitazone and Actos pioglitazone to warn

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE